NYSE: OGEN - Oragenics, Inc.

Rentabilidade por seis meses: -43.31%
Rendimento de dividendos: 0.00%
Setor: Healthcare

Cronograma de promoção Oragenics, Inc.


Sobre a empresa Oragenics, Inc.

Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification.

mais detalhes
The company also develops NT-CoV2-1, a SARS-CoV-2 vaccine product candidate; and Lantibiotic Product Candidate, such as Mutacin 1140 (MU1140), a molecule belonging to the novel class of antibiotics. It has a license agreement with Inspirevax Inc. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.

IPO date 2004-02-25
ISIN US6840233026
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.oragenics.com
Цена ао 0.2462
Alteração de preço por dia: -7.65% (0.234)
Alteração de preço por semana: -16.88% (0.26)
Alteração de preço por mês: -22.82% (0.28)
Alteração de preço em 3 meses: -52.35% (0.4535)
Mudança de preço em seis meses: -43.31% (0.3812)
Mudança de preço por ano: -84.99% (1.44)
Mudança de preço em 3 anos: -39.64% (0.358)
Mudança de preço em 5 anos: -58.95% (0.5264)
Mudança de preço desde o início do ano: -42.83% (0.378)

Subestimação

Nome Significado Nota
P/S 315.47 1
P/BV -13.5 0
P/E 0 0
EV/EBITDA -0.2201 0
Total: 2.75

Eficiência

Nome Significado Nota
ROA, % -328.26 0
ROE, % -714.95 0
Total: 1.67

Dividendos

Nome Significado Nota
Div yield, % 0 0
DSI 0 0
Total: 0.1886

Obrigação

Nome Significado Nota
Debt/EBITDA -0.0311 10
Total: 10

Impulso de crescimento

Nome Significado Nota
Rentabilidade Revenue, % -95.99 0
Rentabilidade Ebitda, % -60.16 0
Rentabilidade EPS, % -94.31 0
Total: 0



Supervisor Cargo Pagamento Ano de nascimento
Mr. Charles L. Pope CPA Executive Chairman 1952 (73 ano)
Mr. Joseph Michael Redmond President & Interim Principal Executive Officer 1961 (64 ano)
Ms. Janet Huffman CFO, Secretary & Treasurer 1972 (53 ano)
Dr. James P. Kelly M.A., M.D. Chief Medical Officer & Member of Scientific Advisor
Dr. William Franklin Peacock IV, F.A.C.E.P., FACC, M.D. Chief Clinical Officer

Endereço: United States, Tampa, 4902 Eisenhower Boulevard - abrir no Google Maps, abrir mapas Yandex
Site: https://www.oragenics.com